Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextenza in Dry Eye Disease
NCT04527887Phase 4Terminated
- Sponsor
- Tufts Medical Center
- Start
- Sep 2020
- Primary completion
- Nov 2023
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in dry eye disease (DED) comparing Dextenza with Placebo (2 arms). Primary endpoint: Change in ocular inflammation at 1 month. Started Sep 2020; status: terminated.
02
Drugs
ozurdex
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04527887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04527887.